NAD+ for Brain Fog: What Human Cognition Trials Show

NAD+ has not been established as a treatment for brain fog. Human research on the precursor nicotinamide riboside, or NR, includes cognition trials, but a higher blood NAD+ level has not reliably translated into better thinking or memory. In a 2026 mild-cognitive-impairment trial, NR raised NAD+ without improving the primary cognitive outcome over 12 weeks ¹.

Brain fog describes a difficulty someone experiences, not one specific diagnosis. For a useful comparison of the ingredients behind the marketing, start with NAD+ versus NMN versus NR. A finding for oral NR should not be presented as evidence for every NAD+ product.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

Peter MD

Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan

See Peter MD↗

Brain fog, MCI and dementia are different questions

Someone describing brain fog may mean slower thinking, trouble concentrating, word-finding difficulty or forgetfulness. That description does not establish an NAD+ deficiency, mild cognitive impairment (MCI) or Alzheimer's disease.

The National Institute on Aging distinguishes memory complaints, MCI and dementia and explains that assessment can identify different causes, including medicines and other health conditions ². The study population therefore matters: a result in older adults with a diagnosed impairment cannot simply be applied to a younger person struggling to concentrate after poor sleep.

When reading a claim, identify the problem the researchers actually studied. Was it a participant's own symptom rating, performance on a cognitive test, an imaging measure or a blood marker? These outcomes may be related, but they answer different questions.

What the 2023 NR trial found

First published online in 2023, with a 2024 journal issue, this randomized pilot enrolled 20 older adults with MCI and escalated oral NR to 1 gram daily during a 10-week study. Blood NAD+ increased substantially, and the target dose was tolerated. However, cognitive and psychometric measures did not show an improvement attributable to NR ³.

The study also explored brain blood flow and epigenetic measures. Those findings did not establish relief of day-to-day brain fog, and the authors noted that the blood-flow significance would not withstand correction for multiple comparisons ³.

The distinction is practical: a study can demonstrate that someone absorbed a precursor and changed a biomarker while leaving the symptom they care about unresolved. A supplement advertisement that mentions only the NAD+ increase leaves out that distinction.

The 2026 MCI study adds a newer test

The 2026 phase-II pilot tested oral NR in adults with amnestic MCI over 12 weeks. Forty-two participants completed the study: 22 in the NR group and 20 receiving placebo. NR approximately doubled blood NAD+, with no serious adverse effects reported, but it did not improve cognitive function, the primary outcome ¹.

There was also no improvement in total cerebral blood flow or blood pressure. Exploratory regional blood-flow observations, including in the hippocampus, were hypotheses for further study rather than proof of a clinical cognitive benefit ¹.

This does not prove that every possible dose, duration or population would have the same result. It does mean that “raises NAD+” should not be used as shorthand for “improves memory.” The trial does not establish a treatment for Alzheimer's disease or a general brain-fog regimen.

What about NAD+ injections or IV therapy?

The MCI trials discussed above used oral NR. They did not test an NAD+ infusion, a home injection or nasal spray for brain fog. Changing the route is not a minor detail when the claim depends on a particular molecule reaching a particular tissue and producing a useful effect.

The IV evidence review explains the limits of that route's human research. For a proposed injection program, use the injection evidence guide to separate formulation-specific claims from studies of oral precursors. A clinic should identify the evidence for the product it proposes, not just a study mentioning NAD metabolism.

Match the research to the reason for the symptom

Brain-fog complaints can arise in different contexts. Our Long COVID evidence review addresses that population separately, while NMN and sleep research asks a different question about sleep-related outcomes. Neither should be treated as interchangeable with an MCI study.

Similarly, feeling more energetic is not the same as demonstrating a change on a cognitive test. The NAD+ energy review discusses that distinction. If a testimonial moves between fatigue, motivation and memory as if they were one measured outcome, the claimed benefit becomes hard to evaluate.

Describe the actual difficulty at an appointment: what changed, when it began and how it affects work or daily tasks. Bring the medicine and supplement list, including any recent changes. NIA emphasizes evaluating concerning cognitive changes and considering potentially treatable causes ². Buying a booster before understanding the problem can make the decision less clear.

What would convincing evidence look like?

A useful brain-fog trial would define the participants' problem before treatment, specify the exact formulation and route, use an appropriate comparison and report a meaningful cognitive or symptom outcome. It would also report adverse events and follow participants long enough to interpret the result.

A higher blood marker alone would not satisfy that question. Neither would an improvement that appears only after searching through many exploratory measures. Ask whether the main outcome improved, whether the comparison was statistically and clinically meaningful, and whether the participants resembled the people targeted by the advertisement.

Those questions are especially relevant when a seller recommends a long prepaid course. The study duration describes a research protocol; it does not establish how long someone with an unrelated symptom should purchase a product.

A reasonable decision before paying for treatment

Ask the clinician what explanation for the cognitive complaint is being considered, which assessment is appropriate and what an optional NAD-related product is expected to change. Agree on how any change would be judged and who will review a new or worsening symptom.

Our NAD+ test guide explains why a measured level is not a standalone diagnosis of the cause of brain fog. For now, the human cognition trials provide a useful caution: successful NAD+ elevation and successful treatment are separate outcomes. The evidence supports continued investigation, but it does not justify promising sharper thinking from an NAD+ subscription.